MAY 29, 2018 4:30 PM PDT

Potential New Treatment to Block the Mechanism for Cancer Metastasis

WRITTEN BY: Mauri Brueggeman

In the last year, researchers have been looking closely at the cellular process of metastasis.  This spread of cancer within the body to distant sites makes therapeutic approaches more complicated.  Metastases remain difficult to treat for all cancer types, hence to examination into the process of metastasis to attempt to inhibit it before the process starts.  One area of focus is the perinucleolar region, which is usually referred to as the perinucleolar compartment (PNC).  This structure is located within the nucleus of a cancer cell.  Most of us learn about the nucleus and perhaps many also know the nucleolus.  The nucleus is where our DNA is stored.  The nucleolus is a small, usually spherical, structure within the nucleus; it is the site of rRNA transcription, processing, and ribosomal generation in transformed or various cancer tissues.  It is visualized microscopically when a cell is in interphase and is rarely found in normal cells. 

The critical component within the PNC identified recently is a compound called metarrestin.  According to the authors of the study, metarrestin disrupts the nucleolar structure and inhibits RNA polymerase I transcription via a translation elongation factor called eEF1A2.  Researchers found that metarrestin inhibited cancer cell invasion in vitro and in three separate mouse models of human cancer.  One of the mouse models had metastatic pancreatic cancer and survival was extended; the study also found that no organ toxicity or adverse effects were observed.

The newest study, published May 16, 2018, in the journal Science & Translational Medicine looked at pancreatic cancer effects in mouse models as described.  Additional research has been published in the past year with focus on other mouse models of cancer including lung and liver metastases of prostate cancer and breast cancer.  Liver histology reports included in the newest study show the metastatic tumors in liver tissue prior to treatment with metarrestin.  The after-treatment histology shows significant reduction in tumor presence.  Therefore, a novel approach to metastasis treatment could be to disrupt the protein-making apparatus within the metastatic cell itself.  If it cannot produce proteins and replicate itself, the cell fails to thrive and so growth stalls.

The group working on this research are collaborators from the National Institutes of Health, Northwestern University Feinberg School of Medicine, the National Center for Advancing Translational Sciences (NCATS)- Chemical Genomic Center, and the NCATS-Bridging Interventional Development Gaps program.  Together these professionals are gathering data on metarrestin needed to further its development as a clinical drug including application to the Federal Drug Administration for an Investigational New Drug status.  These are the steps needed to start the process of using metarrestin on patients as part of clinical trials.

Sources: Science & Translational Medicine, NIH National Center for Advancing Translational Sciences, Gynecologic Oncology, Cancer Research, Cold Spring Harbor Perspectives in Biology Journal,

About the Author
MEd
Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUL 28, 2022
Clinical & Molecular DX
Pancreatic Cancer is Difficult to Detect in its Curable Early Stages: AI Could Soon Change This
JUL 28, 2022
Pancreatic Cancer is Difficult to Detect in its Curable Early Stages: AI Could Soon Change This
Pancreatic cancer typically does not cause symptoms until after it has spread to other organs. This makes it very diffic ...
AUG 09, 2022
Immunology
New Small Molecule May Improve Immunotherapy for a Variety of Cancers
AUG 09, 2022
New Small Molecule May Improve Immunotherapy for a Variety of Cancers
Scientists have been trying to stimulate the immune system to fight cancer for decades, and recent years have brought ma ...
SEP 11, 2022
Microbiology
Using Yeast Cells to Make a Cancer Treatment
SEP 11, 2022
Using Yeast Cells to Make a Cancer Treatment
Vinblastine and vincristine are both common chemotherapies that are used to treat several types of cancer. The drugs sto ...
SEP 15, 2022
Immunology
How a Cancer-Causing Virus Evades Human Immunity
SEP 15, 2022
How a Cancer-Causing Virus Evades Human Immunity
While our immune system is usually able to identify and destroy pathogenic invaders like bacteria and viruses, those mic ...
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
OCT 24, 2022
Technology
3D Printing Breast Cancer Tumors
OCT 24, 2022
3D Printing Breast Cancer Tumors
Breast cancer is among the most common types of cancer, particularly among women. In fact, other than skin cancers, it i ...
Loading Comments...